TY - JOUR T1 - More than smell - COVID-19 is associated with severe impairment of smell, taste, and chemesthesis JF - medRxiv DO - 10.1101/2020.05.04.20090902 SP - 2020.05.04.20090902 AU - Valentina Parma AU - Kathrin Ohla AU - Maria G. Veldhuizen AU - Masha Y Niv AU - Christine E Kelly AU - Alyssa J. Bakke AU - Keiland W. Cooper AU - Cédric Bouysset AU - Nicola Pirastu AU - Michele Dibattista AU - Rishemjit Kaur AU - Marco Tullio Liuzza AU - Marta Y. Pepino AU - Veronika Schöpf AU - Veronica Pereda-Loth AU - Shannon B Olsson AU - Richard C Gerkin AU - Paloma Rohlfs Domínguez AU - Javier Albayay AU - Michael C. Farruggia AU - Surabhi Bhutani AU - Alexander W. Fjaeldstad AU - Ritesh Kumar AU - Anna Menini AU - Moustafa Bensafi AU - Mari Sandell AU - Iordanis Konstantinidis AU - Antonella Di Pizio AU - Federica Genovese AU - Lina Öztürk AU - Thierry Thomas-Danguin AU - Johannes Frasnelli AU - Sanne Boesveldt AU - Özlem Saatci AU - Luis R. Saraiva AU - Cailu Lin AU - Jérôme Golebiowski AU - Liang-Dar Hwang AU - Mehmet Hakan Ozdener AU - Maria Dolors Guàrdia AU - Christophe Laudamiel AU - Marina Ritchie AU - Jan Havlícek AU - Denis Pierron AU - Eugeni Roura AU - Marta Navarro AU - Alissa A. Nolden AU - Juyun Lim AU - KL Whitcroft AU - Lauren R Colquitt AU - Camille Ferdenzi AU - Evelyn V Brindha AU - Aytug Altundag AU - Alberto Macchi AU - Alexia Nunez-Parra AU - Zara M. Patel AU - Sébastien Fiorucci AU - Carl M Philpott AU - Barry C. Smith AU - Johan N. Lundström AU - Carla Mucignat AU - Jane K. Parker AU - Mirjam van den Brink AU - Michael Schmuker AU - Florian Ph.S Fischmeister AU - Thomas Heinbockel AU - Vonnie D.C. Shields AU - Farhoud Faraji AU - Enrique Santamaría AU - William E.A. Fredborg AU - Gabriella Morini AU - Jonas K. Olofsson AU - Maryam Jalessi AU - Noam Karni AU - Anna D’Errico AU - Rafieh Alizadeh AU - Robert Pellegrino AU - Pablo Meyer AU - Caroline Huart AU - Ben Chen AU - Graciela M. Soler AU - Mohammed K. Alwashahi AU - Antje Welge-Lüssen AU - Jessica Freiherr AU - Jasper H. B. de Groot AU - Hadar Klein AU - Masako Okamoto AU - Preet Bano Singh AU - Julien W. Hsieh AU - GCCR Group Author AU - Danielle R Reed AU - Thomas Hummel AU - Steven D. Munger AU - John E. Hayes AU - Olagunju Abdulrahman AU - Pamela Dalton AU - Carol H. Yan AU - Vera V. Voznessenskaya AU - Jingguo Chen AU - Elizabeth A. Sell AU - Julie Walsh-Messinger AU - Nicholas S. Archer AU - Sachiko Koyama AU - Vincent Deary AU - S. Craig Roberts AU - Hüseyin Yanik AU - Samet Albayrak AU - Lenka Martinec Nováková AU - Ilja Croijmans AU - Patricia Portillo Mazal AU - Shima T. Moein AU - Eitan Margulis AU - Coralie Mignot AU - Sajidxa Mariño AU - Dejan Georgiev AU - Pavan K. Kaushik AU - Bettina Malnic AU - Hong Wang AU - Shima Seyed-Allaei AU - Nur Yoluk AU - Sara Razzaghi-Asl AU - Jeb M. Justice AU - Diego Restrepo Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/24/2020.05.04.20090902.abstract N2 - Recent anecdotal and scientific reports have provided evidence of a link between COVID-19 and chemosensory impairments such as anosmia. However, these reports have downplayed or failed to distinguish potential effects on taste, ignored chemesthesis, generally lacked quantitative measurements, were mostly restricted to data from single countries. Here, we report the development, implementation and initial results of a multi-lingual, international questionnaire to assess self-reported quantity and quality of perception in three distinct chemosensory modalities (smell, taste, and chemesthesis) before and during COVID-19. In the first 11 days after questionnaire launch, 4039 participants (2913 women, 1118 men, 8 other, ages 19-79) reported a COVID-19 diagnosis either via laboratory tests or clinical assessment. Importantly, smell, taste and chemesthetic function were each significantly reduced compared to their status before the disease. Difference scores (maximum possible change ±100) revealed a mean reduction of smell (−79.7 ± 28.7, mean ± SD), taste (−69.0 ± 32.6), and chemesthetic (−37.3 ± 36.2) function during COVID-19. Qualitative changes in olfactory ability (parosmia and phantosmia) were relatively rare and correlated with smell loss. Importantly, perceived nasal obstruction did not account for smell loss. Furthermore, chemosensory impairments were similar between participants in the laboratory test and clinical assessment groups. These results show that COVID-19-associated chemosensory impairment is not limited to smell, but also affects taste and chemesthesis. The multimodal impact of COVID-19 and lack of perceived nasal obstruction suggest that SARS-CoV-2 infection may disrupt sensory-neural mechanisms.Competing Interest StatementJohn E. Hayes has received speaking, travel, and consulting fees from federal agencies, nonprofit organizations, commodity boards, and corporate clients in the food industry. Additionally, the Sensory Evaluation Center at Penn State conducts routine product testing for industrial clients to facilitate experiential learning for students. None of these organizations were involved in the conception, design or execution of this project, or the decision to publish these findings. The findings and conclusions in this publication belong solely to the authors, and do not represent the views of the US Government, and do not represent any US Government determination, position, or policy. Thomas Hummel reports grants from Aspuraclip, Berlin, Germany, grants from Sony, Stuttgart, Germany, grants from Smell and Taste Lab, Geneva, Switzerland, grants from Takasago, Paris, France, outside the submitted work. Jeb Justice is a consultant for Medtronic, Inc and Intersect ENT. Christine Kelly is the founder of AbScent. AbScent is a charity registered in England and Wales 1183468.Funding StatementThis work was supported financially with discretionary funds from the Pennsylvania State University (Penn State), including a gift from James and Helen Zallie given in support of Sensory Science at Penn State.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol complies with the revised Declaration of Helsinki and was approved as an exempt study by the Office of Research Protections at The Pennsylvania Study University (Penn State) in the U.S.A. (STUDY00014904).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be available at the OSF project: osf.io/a3vkw http://osf.io/a3vkw ER -